You are here: Home News mesothelioma 05-06
  • Increase font size
  • Default font size
  • Decrease font size
Search

mesothelioma

Mesothelioma News 05-06

Title Filter     Display # 
# Article Title
1 Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed
2 Thoracic Cancer Patients Find New Reasons for Hope with Alimta (pemetrexed)
3 The Mesothelioma Charter - Mesothelioma Web
4 Osteopontin as a marker for pleural mesothelioma
5 Biogen Idec Gene Drug Gives Mesothelioma Patient Second Chance
6 Morphotek Announces IND Submission for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers
7 Promising Research in Early Detection of Mesothelioma
8 ONCONASE (ranpirnase) for unresectable malignant mesothelioma
9 Phase III Program ofONCONASE for The Treatment of Patients with Unresectable Malignant Mesothelioma
10 Scientist Reveals His Hopes for Better Tumour Treatment
11 Alfacell Says Onconase Clinical Trial Enrollment Expected to Be Ahead of Schedule
12 ONCONASE Phase IIIb Registration Study in Unresectable Malignant Mesothelioma
13 Onconase Phase IIIb Confirmatory Registration Trial; First Interim Analysis Data
14 CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for Mesothelioma
15 Mesothelioma Treatment product candidate SS1P renamed CAT-5001
16 Mesothelioma Treatment - Resources for Mesothelioma Patients
17 Alimta Researchers Recognized As Heroes Of Chemistry
18 Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma
19 Zolinza becomes first approved HDAC inhibitor
20 Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer
21 Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors
22 Alfacell Corporation Files for U.S. Orphan Drug Designation for Onconase